Rucaparib

  • Innovator Brand Name - Rubraca
  • API - Rucaparib
  • Packaging - 60 Tablets
  • Strength - 200 mg, 300 mg

What is Rucaparib and what it is used for:

Rucaparib is a PARP inhibitor used as an anti cancer agent for the treatment of patients with advanced ovarian and prostate cancers.

GET PRICE
Dosage

The recommended dose of Rucaparib is 600 mg (two 300 mg rucaparib tablets) administered orally twice daily either with or without food. Treatment should be continued until disease is progressive or unacceptable toxicity occurs. In case a patient misses a dose of rucaparib, instruct the patient to administer the next rucaparib dose at its scheduled time. The vomited doses of rucaparib should not be replaced.

side effects

Most commonly reported rucaparib side effects include increased levels of creatinine, nausea, low red blood cell counts, tiredness or weakness, liver enzymes in the blood, low levels of platelets, decreased appetite, taste disturbances, vomiting, diarrhoea, and belly ache.

Warnings And Precautions
  • Patients with Rubraca should be monitored for complete blood counts for cytopenia at baseline and monthly thereafter for significant changes during treatment.
  • The rucaparib uses are avoided during pregnancy, as it may be responsible for causing fetal harm when used by pregnant women.
  • Due to the potential for serious side effects in breast-fed children from Rubraca, lactating women should not breastfeed while on Rubraca therapy and for 2 weeks after the last dose.
  • Do not spend time in sunlight. Rubraca can make a patient’s skin sensitive to the sun (photosensitivity). Patients may sunburn easily during treatment with rucaparib 300 mg or 200mg.
How Supplied/Storage and Handling:

Care should be exercised in the handling of Rucaparib. Tablets should not be opened or broken. Store Rubraca tablets at room temperature between 68°F-77°F (20°C to 25°C).

Drug interaction of RUCAPARIB

Co-administration of rucaparib tablets may increase the systemic exposure of CYP1A2, CYP3A, CYP2C9, or CYP2C19 substrates, which can increase the risk of toxicities of these medicines. Adjust the dosage of CYP1A2, CYP3A, CYP2C9, or CYP2C19 substrates, in case clinically indicated. If co-administration with warfarin (a CYP2C9 substrate) cannot be avoided, consider increasing the frequency of international normalized ratio (INR) monitoring.

Commonly asked questions:

The innovator/manufacturer decides the cost of Rucaparib medicine. It has no authority to be marketed in India yet. Still, Ikris Pharma Network can help the patients access this medicine under its Named patient import programme (a programme under which an organization allows you to access the medication on a patient’s name legally in your country). The named patient import programme acts as a bridge between patients and manufacturers to access the medicine from any part of the world to India.

Rucaparib specifically belongs to the class of drugs named poly (ADP-ribose) polymerase (PARP) inhibitors. 

The recommended dose of rucaparib tablets should be administered orally twice daily with or without food.

Disclaimer

All Trademarks and Brands that appear on the website belong to their respective owners and Ikris Pharma Network does not lay and claim on them we only provide Information. Rucaparib Tablets is a pharmaceutical drug that legally requires a medical prescription to be dispensed.

Following Information meant for Wholesalers, Suppliers, Exporters, Doctors, Comparator Supplies, Hospitals, Generic, Brand, Corporate Sourcing, Reseller and Pharmacies.